When a peptide will not dissolve in aqueous buffer, a structured approach to co-solvents and pH is more productive than simply adding more DMSO.
Key Takeaways
- Adjusting pH away from the isoelectric point is usually the most effective first move and introduces no excipient.
- Low concentrations of polysorbate or poloxamer can keep hydrophobic peptides in solution by reducing interfacial adsorption.
- A clear solution is not proof of molecular dispersion.
Start with pH, not solvent
Adjusting pH away from the isoelectric point is usually the most effective first move and introduces no excipient. Determine the solubility profile across pH before reaching for organic co-solvents.
Acceptable co-solvents
DMSO, propylene glycol, ethanol, and PEG 300 or 400 are commonly used. Each has compatibility limits for the intended route, and DMSO in particular is problematic beyond small percentages in injectable presentations.
For related mechanism work, see nasal peptide delivery.
Surfactant-assisted solubilisation
Low concentrations of polysorbate or poloxamer can keep hydrophobic peptides in solution by reducing interfacial adsorption. The approach is widely used but surfactant quality and degradation products must be controlled.
Cyclodextrin complexation
Cyclodextrins form inclusion complexes with hydrophobic side chains and can raise apparent solubility substantially. The binding is peptide-specific, so the benefit has to be demonstrated rather than assumed from other sequences.
Verifying true solubility
A clear solution is not proof of molecular dispersion. Confirm by filtration followed by concentration measurement, or by dynamic light scattering, since apparent clarity is compatible with the presence of soluble aggregates.
Experimental Conditions and Practical Setup
A solubilisation screen tests pH first, then co-solvent percentage, then surfactant or cyclodextrin, holding everything else constant. After each trial the solution is filtered and the peptide concentration measured, so that apparent solubility is distinguished from a dispersion that merely looks clear.
Co-solvent options and route constraints
| Co-solvent | Useful for | Constraint |
|---|---|---|
| DMSO | Very hydrophobic sequences | Low tolerated percentage in injectables |
| Propylene glycol | Moderate solubilisation | Tonicity and tolerability |
| Ethanol | Lipophilic peptides | Limited percentage, volatility |
| PEG 300 or 400 | General solubilisation | Viscosity at higher levels |
Practical Notes for the Bench
- Establish the pH-solubility profile before using co-solvents.
- Confirm molecular dispersion, not just visual clarity.
- Check route-specific limits on each co-solvent.
Frequently Asked Questions
How much DMSO is acceptable?
It depends entirely on the route; for injectable work the tolerated percentage is low, so dilution and alternative solvents should be considered.
Is a clear solution soluble?
Not necessarily. Soluble aggregates can produce a clear appearance, so confirm by filtration and concentration measurement.
Do cyclodextrins always help?
No. Complexation is peptide-specific and the benefit must be demonstrated for each sequence.
How do I verify that a clear solution is truly dissolved?
Filter it and measure the concentration afterwards, or use dynamic light scattering. Visual clarity is compatible with the presence of soluble aggregates.
Related Reading
- nasal peptide delivery
- peptide sustained release
- injectable peptide formulation
- peptide circular dichroism
- peptide vaccine design
References & Further Reading
- Ran Y et al. Solubilization of cyclosporin A. AAPS PharmSciTech. 2001. PubMed 14727890
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
Content here is written for researchers handling peptide reagents. It does not constitute medical guidance, dosing advice, or an endorsement of any supplier.
Reviewed by Priya Raghunathan, MSc, Formulation & Stability Science.